Patient Rating:

4.7 out of 5

205 Patient Ratings
55 Patient Comments

Neeraj Agarwal, M.D.

Specialties

Languages

  • English

Clinical Details

Locations

Schedule An Appointment Clinical Office Address
(801) 585-0250 Huntsman Cancer Hospital
Clinic 2B, GU
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Neeraj Agarwal, MD

Assistant Professor, Division of Oncology, Department of Medicine

Neeraj Agarwal, MD, is an assistant professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine; and the Director of the “Genitourinary Oncology Multidisciplinary Program” at the Huntsman Cancer Institute (HCI). He is also an investigator at Huntsman Cancer Institute and member of the Experimental Therapeutics Program.

As a specialist in adult hematology and oncology, Dr. Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder, and testes).

Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, and the Southwest Oncology Group (SWOG). After receiving his MBBS degree from Assam Medical College and MD from All India Institute of Medical Sciences, in New Delhi, India, Dr. Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine, at the University of Iowa. He then completed a hematology-oncology fellowship at the HCI and the University of Utah School of Medicine.

Dr. Agarwal serves as the national principle investigator and chair of a multicentre phase III clinical trial for men with newly diagnosed metastatic prostate cancer. This trial is sponsored by SWOG, one of the largest National Cancer Institute’s (NCI) clinical trial group, and endorsed by all major groups in NCI Clinical Trials Network ( ECOG, CALGB etc). This trial is expected to recruit more than 1500 men with newly diagnosed metastatic prostate cancer across the United States. In addition, he is the principle investigator for two investigator initiated clinical trials for men with prostate cancer. Dr. Agarwal has received several awards and grants and has authored more than 50 peer reviewed articles and book chapters. He has given talks at several prestigious regional and national forums, including the workshop at the National Institute of Health’s National Institute on Aging, Utah Urologic Society Annual meeting, and MD Anderson Cancer Center’s–sponsored oncology conferences. He serves as a panel member for the National Comprehensive Cancer Network (NCCN) guideline- committees for bladder, kidney cancer and testicular cancer

Dr. Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr. Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine.

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Sub: Geriatric Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending doctor
4.8
My confidence in doctor
4.8
Time doctor spent with me
4.7
Doctor spoke using clear language
4.8
Doctor's effort to include me in decisions
4.7
Doctor's concern for questions & worries
4.8
Doctor's explanation of condition/problem
4.7
Wait time at clinic
4.2
Doctor's friendliness and courtesy
4.7

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

March 30, 2014

Staff know what they are doing and make things easier for family to understand more about my illness.

March 02, 2014

The staff and doctors were excellent!

February 22, 2014

Seems like I spend a lot of time at Huntsman. Everyone is always very nice and courteous! I have never had a bad experience! The Valet service is a huge plus especially when you might not be having the best of days! My hat off to everyone!

February 12, 2014

All good

February 12, 2014

Professional, congenial, and clearly caring in every way. I was pampered and treated like a friend or family member. I am convinced my welfare and wellbeing really matters to the folks at HCC

February 12, 2014

Dr. Agarwal spent a lot of time outlining different treatment options, most of which were not really an option for me. He also mentioned more than once he had other patients he needed to see. He did ask form one of the Nurses in the IL-2 treatment to come talk with us. She added a lot to what he said. I was called on the following day to let me know about an appointment on that Monday they had scheduled for me in Radiology without having addressed that during my appointment.

February 10, 2014

Could not have asked for better people.

February 07, 2014

Instilled a positive attitude in a stressful situation.

January 20, 2014

Outstanding

January 18, 2014

Always perfect.

January 17, 2014

A lot of variation between Dr, PA and Nurses

January 13, 2014

Excellent

January 09, 2014

Outstanding in each of these categories. I did not think the physician and his assistant would have the kind of time for patient I received from both. I felt uniquely special and cared for and about. Thank you to Dr. Agarwal and Julia.

December 16, 2013

The PA went out of her way to help me understand, She made a graft on the computer to show me the answer a question I had.

November 20, 2013

They are so good to explaining everything.

October 28, 2013

We have already recommended Huntsmans to a coworker with a newly diagnosed cancer.

October 02, 2013

good

September 20, 2013

care provider made me feel I was the only patient he had.

August 26, 2013

Every visit I've made to this clinic has always been a good experience.

August 20, 2013

Dr Agarwal and the nurse practitioners have always been great. They clearly have out best interest at heart and seem invested in us and our progress towards a cure. This time we also saw Steve - pharmacist - he was just as kind as could be and very informative. It is just great how all the disciplines seem to be there, on the spot, when needed.

August 19, 2013

Dr. Agerwal is the best!!! We love him

August 08, 2013

Dr. Agerwal is always concerned, kind and willing to answer all questions to our satisfaction.

July 22, 2013

I am very confident in Dr. Agarwall. He always takes the time to make sure I understand what is going on even though I have been doing whole brain radiation and get confused often.

July 08, 2013

Again, very impressed and grateful to all.

June 02, 2013

Everyone was most concerned and helpful.

May 29, 2013

Great experience

April 22, 2013

I truly don't know what we would ever do with our Doctor! He is amazing and kind and we know that he truly cares and wants the very best for my husband. He is an amazing man!!!

April 01, 2013

Every experience I have had at Huntsman has been great. I look forward to driving down from Idaho to not only be treated but vcisit with Doctors and staff. Don't chgange anything.

March 12, 2013

The visit was very helpful. I felt quite confident about the info.

March 04, 2013

Dr Agarwal went out of his way to make sure that we understood the risk/reward of the IL 2 therapy, included us in the decision making process, and also welcomed a friend who was sitting on on the session. We left feeling completely confident in the care we would receive from Dr Agarwal and the Nurse practitioners who administer the treatment.

March 04, 2013

I always feel that everyone is proactively involved in my case and has a personal interest in my progress. I know I am in good hands at the Huntsman.

February 25, 2013

Narraj is great and is so caring.

February 25, 2013

As usual. Unbelievable care.

February 18, 2013

I have recommended and I will continue to recommended my care provider Dr Neeraj Agarwal and his staff to others. I appreciate their committed positive approach to my treatment.

February 10, 2013

I frequently mention to others about the good experience I have had at HCC. The level of treatment and experience of the doctors is exceptional. The treatment and the facility are world class! Thank you

January 28, 2013

This visit is the best one I have experienced so far. Keep up the good work.

January 14, 2013

Pleasantly surprised at the knowledge the provider had of my case upon arrival without looking at notes and the unrushed atmosphere and amount of time spent with me.

November 27, 2012

We told them about my "flu like" symptoms after my first infusion and they immediately recommended changes in the procedure that would help me to avoid those "flu like" symptoms in the future

November 12, 2012

Every one is great!!!!!!!!!!

November 12, 2012

The entire Staff at HCI is on the cutting edge in their profession. I have the highest confidence in their direction and treatment.

October 29, 2012

If you have Cancer, This is the place to come to for treatment.

October 22, 2012

Dr. Agarawal was very clear, professional and straightforward in his manner.

October 12, 2012

I can understand how a Doctor's schedule can be disrupted. I do not understand why I was not better informed of reason for the delay. I certainly do not know why I waited in the Infusion Clinic for nearly 90 minutes because, as I understand, Pharmacy was slow.

July 30, 2012

I personaly do not like the doctor

July 16, 2012

We tell everyone this is the best place for excelant care.

June 26, 2012

Dr. Agarwal is apparently very knowledgeable and proficient medically, but I have found his patient concern and communication skills to be lacking. He demonstrates superficial concern and does a very marginal job of explaining his treatments and taking time to insure that the patient has a comfortable understanding of treatment/changes in treatments. He gives the distinct impression that his "schedule" and clinical studies are much more important that your concerns/comfort level.

June 25, 2012

they were busy that day but I had no problem

May 04, 2012

GOOD

April 13, 2012

thanks for the great care I have been afford in helping me fight my cancer.

March 23, 2012

Dr. who spoke to us and examined me before Dr. Agarwal was very knowledgeable, and during exam found a potential concern which he told him about.

March 16, 2012

good

February 29, 2012

In the three years I have been at the Huntsman Center I can say it has been a pleasant experience and I would highly recommend it to everyone

February 08, 2012

Good experience

January 27, 2012

I was well taken care of. I didn't know what to expect. I trust these people to do their best for me.

January 10, 2012

Very good.

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Sub: Geriatric Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-0255 Huntsman Cancer Institute
Oncology
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Neeraj Agarwal, MD

Assistant Professor, Division of Oncology, Department of Medicine

Neeraj Agarwal, MD, is an assistant professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine; and the Director of the “Genitourinary Oncology Multidisciplinary Program” at the Huntsman Cancer Institute (HCI). He is also an investigator at Huntsman Cancer Institute and member of the Experimental Therapeutics Program.

As a specialist in adult hematology and oncology, Dr. Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder, and testes).

Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, and the Southwest Oncology Group (SWOG). After receiving his MBBS degree from Assam Medical College and MD from All India Institute of Medical Sciences, in New Delhi, India, Dr. Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine, at the University of Iowa. He then completed a hematology-oncology fellowship at the HCI and the University of Utah School of Medicine.

Dr. Agarwal serves as the national principle investigator and chair of a multicentre phase III clinical trial for men with newly diagnosed metastatic prostate cancer. This trial is sponsored by SWOG, one of the largest National Cancer Institute’s (NCI) clinical trial group, and endorsed by all major groups in NCI Clinical Trials Network (ECOG, CALGB etc). This trial is expected to recruit more than 1500 men with newly diagnosed metastatic prostate cancer across the United States. In addition, he is the principle investigator for two investigator initiated clinical trials for men with prostate cancer. Dr. Agarwal has received several awards and grants and has authored more than 50 peer reviewed articles and book chapters. He has given talks at several prestigious regional and national forums, including the workshop at the National Institute of Health’s National Institute on Aging, Utah Urologic Society Annual meeting, and MD Anderson Cancer Center’s–sponsored oncology conferences. He serves as a panel member for the National Comprehensive Cancer Network (NCCN) guideline- committees for bladder, kidney cancer and testicular cancer.

Dr. Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr. Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine.

Education

Education History

Type School Degree
Fellowship University of Utah School of Medicine
Hematology/Oncology
Fellow
Fellowship University of Iowa Hospitals and Clinics
Geriatrics
Fellow
Residency University of Iowa Hospitals and Clinics
Internal Medicine
Resident
Internship Advocate Illinois Masonic Medical Center
Internal Medicine
Intern
Professional Medical All India Institute of Medical Sciences
Medicine
M.D.
Professional Medical Assam Medical College
Medicine
M.B.B.S.

Publications

Selected Provider Publications

Journal Article

  1. Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath J(2014)Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.  Targeted Oncology, 9(1),63-71
  2. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky M(2014)Metabolic complications with the use of mTOR inhibitors for cancer therapy.  Cancer Treatment Reviews, 40(1),190-6
  3. Campo RA, Agarwal N, LaStayo PC, O'Connor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney A(2014)Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong.  Journal of Cancer Survivorship, 8(1),60-9
  4. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma (2014)Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.  Clinical Cancer Research, 20(2),480-9
  5. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri T(2014)The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.  European Urology, 65(4),723-30
  6. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde (2014)Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.  Clinical genitourinary cancer, 12(2),130-7
  7. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood L(2014)Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.  Annals of Oncology, 25(1),149-54
  8. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar (2014)Kidney cancer, version 2.2014.  Journal of the National Comprehensive Cancer Network, 12(2),175-82
  9. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang N(2014)Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.  Journal of Clinical Oncology, 32(11),1136-42
  10. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt (2014)New agents for prostate cancer.  Annals of Oncology,
  11. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng D(2013)The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.  Targeted Oncology, 8(3),203-9
  12. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri T(2013)External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.  The Lancet Oncology, 14(2),141-8
  13. Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde (2013)Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.  Clinical genitourinary cancer, 11(3),316-20
  14. Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang N(2013)Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.  Current Urology Reports, 14(3),174-83
  15. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho (2013)Bladder cancer.  Journal of the National Comprehensive Cancer Network, 11(4),446-75
  16. Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney A(2013)Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors.  Integrative Cancer Therapies, 12(6),464-74
  17. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho (2013)Penile cancer: Clinical Practice Guidelines in Oncology.  Journal of the National Comprehensive Cancer Network, 11(5),594-615
  18. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng D(2013)Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.  Cancer, 119(16),2999-3006
  19. Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde (2013)Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.  Clinical genitourinary cancer, 11(4),495-500
  20. Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal (2013)Emerging molecularly targeted therapies in castration refractory prostate cancer.  Prostate Cancer, 2013981684
  21. Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky M(2013)Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.  Targeted Oncology,
  22. Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney A(2013)Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study.  BMC Health Services Research, 13(1),279
  23. Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM J(2013)Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.  The Lancet Oncology, 14(9),893-900
  24. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng D(2013)Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy.LID - S0302-2838(13)00746-X [pii]LID - 10.1016/j.eururo.2013.07.031 [doi]  European Urology,
  25. Nelson Q, Agarwal N, Stephenson R, Cannon-Albright L(2013)A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer.  Frontiers in Genetics, 4152
  26. Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, Aizad H, Hughen RW, Bateman L, Light A(2013)Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.  Psychoneuroendocrinology, 38(12),2983-95
  27. Swierczek S, Agarwal AM, Naidoo K, Lorenzo FR, Whisenant J, Nussenzveig RH, Agarwal N, Coetzer TL, Prchal J(2013)Novel exon 2 alpha spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct alpha spectrin defects.  Haematologica, 98(12),1972-9
  28. Agarwal N, Hussain (2013)Management of hormone-sensitive metastatic prostate cancer.  Hematology - Oncology Clinics of North America, 27(6),1221-41, viii
  29. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, di Lorenzo G, Sternberg CN, Mehta AN, Sonpavde (2013)A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.LID - 10.1111/bju.12564 [doi]  B J U International,
  30. Sangle NA, Mao R, Shetty S, Schiffman JD, Dechet C, Layfield L, Agarwal N, Liu (2013)Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma.  Indian Journal of Pathology & Microbiology, 56(4),428-33
  31. Agarwal N, Sonpavde G, Sternberg C(2012)Novel molecular targets for the therapy of castration-resistant prostate cancer.  European Urology, 61(5),950-60
  32. Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal J(2012)Methylation of AR locus does not always reflect X chromosome inactivation state.  Blood, 119(13),e100-9
  33. Agarwal N, Padmanabh S, Vogelzang N(2012)Development of novel immune interventions for prostate cancer.  Clinical genitourinary cancer, 10(2),84-92
  34. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin R(2012)Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.  Journal of Clinical Oncology, 30(12),1371-7
  35. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder R(2012)Testicular cancer.  Journal of the National Comprehensive Cancer Network, 10(4),502-35
  36. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri T(2012)Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.  The Lancet Oncology, 13(9),927-35
  37. Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister D(2012)A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.  Journal of the National Comprehensive Cancer Network, 10(11),1391-8
  38. Agarwal N, Sonpavde G, Sartor (2011)Cabazitaxel for the treatment of castration-resistant prostate cancer.  Future Oncology (London, England), 7(1),15-24
  39. Chen A, Agarwal (2009)Reversible posterior leucoencephalopathy syndrome associated with sunitinib.  Internal Medicine Journal Online, 39(5),341-2
  40. Lim HY, Agarwal AM, Agarwal N, Ward J(2009)Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer.  Singapore Medical Journal, 50(5),e178-80
  41. Agarwal N, Hussain (2009)Management of bladder cancer: current and emerging strategies.  Drugs, 69(9),1173-87
  42. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang (2009)NCCN clinical practice guidelines in oncology: testicular cancer.  Journal of the National Comprehensive Cancer Network, 7(6),672-93
  43. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang (2009)NCCN clinical practice guidelines in oncology: kidney cancer.  Journal of the National Comprehensive Cancer Network, 7(6),618-30
  44. Agarwal N, Batten (2009)Optimal treatment in the postorchiectomy management of clinical stage I seminoma.  Oncology (Williston Park, N.Y.), 23(9),764, 767
  45. Agarwal N, Prchal J(2009)Anemia of chronic disease (anemia of inflammation).  Acta Haematologica, 122(2-3),103-8
  46. Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, Agarwal N, Anderson (2008)Community physicians' strategies for patients with medically unexplained symptoms.  Family Medicine, 40(2),111-8
  47. Swierczek SI, Agarwal N, Nussenzveig RH, Rothstein G, Wilson A, Artz A, Prchal J(2008)Hematopoiesis is not clonal in healthy elderly women.  Blood, 112(8),3186-93
  48. Werner TL, Agarwal N, Carney HM, Rodgers G(2007)Management of cancer-associated thrombotic microangiopathy: what is the right approach?  American Journal of Hematology, 82(4),295-8
  49. Agarwal N, Spahr JE, Rodgers G(2007)Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa.  Blood Coagulation and Fibrinolysis, 18(2),205-7
  50. Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal J(2007)Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia.  International Journal of Medical Sciences, 4(4),232-6
  51. Nordin TA, Hartz AJ, Noyes R Jr, Anderson MC, Rosenbaum ME, James PA, Ely JW, Agarwal N, Levy B(2006)Empirically identified goals for the management of unexplained symptoms.  Family Medicine, 38(7),476-82
  52. Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal (2001)A study of autoimmune markers in hepatitis C infection.  Indian Journal of Medical Research, The, 113170-4

Review

  1. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde (2010)Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.  Future Oncology (London, England), 6(5),665-79
  2. Agarwal N, Prchal J(2008)Erythropoietic agents and the elderly.  Seminars in Hematology, 45(4),267-75
  3. Agarwal N, Gordeuk RV, Prchal J(2007)Genetic mechanisms underlying regulation of hemoglobin mass.  Advances in Experimental Medicine and Biology, 618195-210
  4. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers G(2006)Acquired amegakaryocytic thrombocytopenic purpura.  American Journal of Hematology, 81(2),132-5

Book Chapter

  1. Agarwal N, Vogelzang NJ(2011)Development of novel immune interventions for genitor-urinary cancers.  ,

Case Report

  1. Narayanan S, Callis-Duffin K, Batten J, Agarwal (2010)Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.  American Journal of the Medical Sciences, 339(6),580-1
  2. Agarwal AM, Agarwal N, Glenn MJ, Lim M(2007)Blastic transformation of low-grade follicular lymphoma.  Journal of Clinical Oncology, 25(16),2326-8
  3. Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading NS, Bailey L, Kutlar A, Prchal J(2007)Missense mutation of the last nucleotide of exon 1 (G->C) of beta globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele.  Haematologica, 92(12),1715-6
  4. Agarwal N, Cherascu (2002)Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine.  Journal of Postgraduate Medicine, 48(3),197-8
  5. Sharma S, Dey AB, Agarwal N, Nagarkar KM, Gujral (1999)Tuberculosis: a rare cause of splenic abscess.  Association of Physicians of India. Journal, 47(7),740-1

Editorial

  1. Agarwal N, Vogelzang N(2011)Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.  ASCP CheckSample Series, 108(2),227-8

Letter

  1. Agarwal (2010)Hormonal therapy for prostate cancer in men with heart disease.  JAMA: The Journal of the American Medical Association, 303(1),32-3; author reply 33
  2. Agarwal N, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal J(2009)Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings?  Blood, 114(11),2357-8; author reply 2358-9
  3. Yoon D, Agarwal N, Prchal J(2008)Does erythropoietin promote tumor growth?  Clinical Cancer Research, 14(6),1920; author reply 1920-1
  4. Wada DA, Agarwal N, Florell SR, Lim M(2008)Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma.  Pathology, 40(3),316-20
  5. Agarwal N, Gordeuk VR, Prchal J(2007)Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed.  Journal of Clinical Oncology, 25(13),1813-4; author reply 1815
  6. Agarwal N, Fletcher D, Ward (2007)Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?  Clinical Cancer Research, 13(13),4027
  7. Agarwal N, Tepe EM, Mishra A, Ward J(2006)Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip.  Annals of Hematology, 85(10),741-2
  8. Agarwal N, Klix MM, Burns C(2004)Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance.  Annals of Internal Medicine, 141(1),83-4

Abstract

  1. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY(In Press)First-, second-, third-line therapy for mRCC: benchmarks for the trial design from the IMDC. Accepted.  ,

Poster

  1. Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N(2014)Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Accepted for Poster Presentation ASCO May 30-June 3, 2014.  ,
  2. Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J(2014)Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Accepted for Poster discussion session at ASCO.  ,
  3. Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E(2014)Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Accepted for poster discussion session at ASCO.  ,
  4. Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N(2014)Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Accepted Poster Presentation for ASCO Meeting May 30-June 3, 2014.  ,
  5. Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S(2014)Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation Accepted for ASCO.  ,
  6. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R(2014)Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Accepted for Poster Presentation at ASCO.  ,
  7. Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I(2014)SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation accepted at ASCO.  ,
  8. Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I(2014)SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691).  ,
  9. Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I(2014)SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster Presentation Accepted for ASCO.  ,

Clinical Trials

Clinical Trials

Video & News